Skandinaviska Enskilda Banken (SEB)’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-48,728
Closed -$1.34M 949
2023
Q4
$1.34M Buy
48,728
+11,900
+32% +$287K 0.01% 651
2023
Q3
$822K Hold
36,828
0.01% 707
2023
Q2
$938K Hold
36,828
0.01% 708
2023
Q1
$821K Sell
36,828
-1,775
-5% -$42.9K 0.01% 717
2022
Q4
$916K Sell
38,603
-2,236
-5% -$52K 0.01% 678
2022
Q3
$678K Sell
40,839
-4,804
-11% -$108K 0.01% 725
2022
Q2
$908K Buy
45,643
+1,642
+4% +$33.2K 0.01% 726
2022
Q1
$1.21M Sell
44,001
-15,641
-26% -$447K 0.01% 731
2021
Q4
$2.47M Hold
59,642
0.01% 598
2021
Q3
$2.77M Buy
59,642
+34,846
+141% +$1.52M 0.02% 562
2021
Q2
$991K Buy
24,796
+363
+1% +$15.5K 0.01% 812
2021
Q1
$1.31M Sell
24,433
-5,729
-19% -$330K 0.01% 771
2020
Q4
$1.48M Sell
30,162
-1,643
-5% -$76.1K 0.01% 732
2020
Q3
$1.03M Sell
31,805
-113
-0.4% -$3.59K 0.01% 728
2020
Q2
$827K Sell
31,918
-40,482
-56% -$1.01M 0.01% 751
2020
Q1
$1.76M Buy
72,400
+46,100
+175% +$1.16M 0.02% 503
2019
Q4
$734K Buy
+26,300
New +$681K 0.01% 759

Other funds holding VCYT

Skandinaviska Enskilda Banken (SEB)'s VCYT Position: Q1 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Veracyte (VCYT) in Q1 2024, closing a stake of 48,728 shares — an estimated $1.34M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in VCYT in Q4 2019 and held it in 17 quarters. The position peaked at $2.77M in Q3 2021. 246 funds tracked by Wall St. Rank hold VCYT as of Q1 2024.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Veracyte position as of Q1 2024 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 48,728 Veracyte shares in Q1 2024, an estimated $1.34M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Veracyte in Q4 2019 and held it in 17 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Veracyte position peaked at $2.77M in Q3 2021.
  • 246 funds tracked by Wall St. Rank held Veracyte as of Q1 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2024, filed 13 May 2024.